CompletedNot Applicable

Early Post-marketing Study of Daclatasvir (Daklinza) in the Treatment of Chronic Hepatitis C (CHC) in Adults

Mexico10 participantsStarted 2015-10-21

Plain-language summary

This early post-marketing study is an observational, prospective and descriptive study of patients receiving daclatasvir for the treatment of Chronic Hepatitis C at participating sentinel sites for the CNFV in Mexico.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Subjects who received daclatasvir as part of a clinical trial.
✕. Subjects who received daclatasvir for any indication other than local approved.
✕. Contraindications included in the approved Mexican prescribing information.

What they're measuring

Number of Adverse Events

Timeframe: Approximately 24 months

Trial details

NCT IDNCT03181074

SponsorBristol-Myers Squibb

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2019-08-19

View on ClinicalTrials.gov More Hepatitis C trials